Trial · NCT00166166
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent Change in Forearm Blood Flow (FBF) After Tetraethylammonium (TEA) Administration | Baseline, 5 minutes | Only 62 of the original 174 subjects were treated for this portion of the study. | percent change | MEAN |
| PRIMARY | Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA) | Baseline, 5 minutes | Only 62 of the original 174 subjects were treated for this portion of the study. | percent change | MEAN |
| SECONDARY | Percent Change in Forearm Blood Flow (FBF) After Administration of L-NG-monomethyl Arginine (L-NMMA) and Tetraethylammonium (TEA) | 5 minutes, 10 minutes | Only 62 of the original 174 subjects were treated for this portion of the study. | percent change | MEAN |
| SECONDARY | Percent Change in Forearm Blood Flow (FBF) After Fluconazole Administration | Baseline, 5 minutes | Only 33 of the original 174 subjects were treated for this portion of the study. | percent change | MEAN |
| SECONDARY | Percent Change in Forearm Blood Flow (FBF) After L-NG-monomethyl Arginine (L-NMMA) and Fluconazole Administration | 5 minutes, 10 minutes | Only 15 of the original 174 subjects were treated for this portion of the study. | percent change | MEAN |
| SECONDARY | Percent Change in Forearm Blood Flow (FBF) After Fluconazole and Tetraethylammonium (TEA) Administration | 5 minutes, 10 minutes | Only 19 of the original 174 subjects were treated for this portion of the study. | percent change | MEAN |
| SECONDARY | Forearm Blood Flow (FBF) After Sodium Nitroprusside Administration | 5 minutes | Only 80 of the original 174 subjects were treated for this portion of the study. | mL min^-1 * 100 mL^-1 | MEAN |
| SECONDARY | Change in Tissue Plasminogen Activator (t-PA) Release | Baseline, 30 minutes | Only 33 of the original 174 subjects were treated for this portion of the study. | ng/mL | MEAN |
| SECONDARY | Change in Tissue Plasminogen Activator (t-PA) Release After Tetraethylammonium (TEA) and Bradykinin Administration | 30 minutes, 60 minutes | Only 18 of the original 174 subjects were treated for this portion of the study. | ng/mL | MEAN |
| SECONDARY | Change in Tissue Plasminogen Activator (t-PA) Release After Fluconazole and Bradykinin Administration | 30 minutes, 60 minutes | Only 11 of the original 174 subjects were treated for this portion of the study. | ng/mL | MEAN |
| SECONDARY | Change in Tissue Plasminogen Activator (t-PA) Release After Fluconazole, Tetraethylammonium (TEA), and Bradykinin Administration | 60 minutes, 90 minutes | Only 10 of the original 174 subjects were treated for this portion of the study. | ng/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00166166/outcomes